Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Feb 27 2023 | New AstraZeneca Podcast Launched Industry News In The News Industry Read More Jan 12 2023 | Newly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure Industry News In The News Industry Read More Dec 14 2022 | Cytokinetics Announces Outcome of FDA Advisory Committee Vote on Omecamtiv Mecarbil Industry News In The News Industry Read More Dec 8 2022 | Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes Industry News In The News Industry Read More Nov 7 2022 | FARXIGA improved symptom burden and health-related quality of life in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 13 Page 14 Page 15 Page 16 Current page 17 Page 18 Page 19 Page 20 Page 21 … Next page Next › Last page Last »
Jan 12 2023 | Newly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure Industry News In The News Industry Read More
Dec 14 2022 | Cytokinetics Announces Outcome of FDA Advisory Committee Vote on Omecamtiv Mecarbil Industry News In The News Industry Read More
Dec 8 2022 | Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes Industry News In The News Industry Read More
Nov 7 2022 | FARXIGA improved symptom burden and health-related quality of life in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More
